Agenus and noetik enter collaboration to develop ai-enabled predictive biomarkers for bot/bal using foundation models of virtual cell biology

Lexington, mass. & san francisco--(business wire)--agenus inc. (nasdaq: agen) a leader in immuno-oncology innovation and noetik, a leader in ai-driven spatial and multimodal biology, today announced a research collaboration to develop predictive biomarkers of response to agenus' lead clinical stage immuno-oncology (io) combination, botensilimab (bot, multifunctional fc-enhanced anti-ctla-4) and balstilimab (bal, anti-pd-1). the collaboration harnesses noetik's proprietary virtual cell foundatio.
AGEN Ratings Summary
AGEN Quant Ranking